<p>根據 Briefing.com 的報道，投資分析師在週四發佈的研究報告中，將 Zentalis Pharmaceuticals（納斯達克股票代碼：ZNTL）的評級從 “買入” 調降至 “中性”。他們目前將該股票的目標價格定為 5.00 美元，低於之前的 28.00 美元。UBS 集團的目標價格表明，相較於公司之前的收盤價，有 20.77% 的潛在上漲空間。</p>
<p>其他股票分析師最近也發佈了關於該公司的研究報告。富國銀行公司將 Zentalis Pharmaceuticals 的評級從 “超重” 調降至 “持平”，並將其目標價格從 29.00 美元降至 9.00 美元。Stifel Nicolaus 將 Zentalis Pharmaceuticals 的目標價格從 32.00 美元降至 10.00 美元，併為該公司設定了 “買入” 評級。摩根士丹利重新確認了 “持平” 評級，並將 Zentalis Pharmaceuticals 的目標股價設定為 8.00 美元（之前為 38.00 美元）。HC Wainwright 將 Zentalis Pharmaceuticals 的目標股價從 40.00 美元降至 20.00 美元，併為該公司設定了 “買入” 評級。最後，Wedbush 將 Zentalis Pharmaceuticals 的股票評級從 “中性” 調降至 “表現不佳”，並將其目標價格從 15.00 美元降至 4.00 美元。一位研究分析師給予該股票賣出評級，六位持有評級，三位給予買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，共識目標價格為 11.33 美元。</p>
<p><strong>閲讀我們對 ZNTL 的最新分析</strong></p>
<h2>Zentalis Pharmaceuticals 股價下跌 50.7%</h2>
<p>週四，Zentalis Pharmaceuticals 股票開盤價為 4.14 美元。該公司市值為 2.9406 億美元，市盈率為-1.24，貝塔係數為 1.83。Zentalis Pharmaceuticals 的 52 周最低價為 3.93 美元，最高價為 30.53 美元。該公司的 50 天簡單移動平均線為 11.53 美元，200 天簡單移動平均線為 13.08 美元。</p>
<p>Zentalis Pharmaceuticals（納斯達克股票代碼：ZNTL）於 5 月 7 日星期二公佈了其季度收益結果。該公司季度每股盈利為 0.14 美元，高於預期的（0.77）美元。該季度公司營收為 4056 萬美元，超過分析師預期的 3500 萬美元。去年同期，該公司每股虧損為（1.07）美元。作為一組，股票分析師預計 Zentalis Pharmaceuticals 今年將每股虧損 2.72 美元。</p>
<h2>Zentalis Pharmaceuticals 內部交易活動</h2>
<p>據相關消息，首席財務官 Cam Gallagher 於 5 月 31 日星期五進行了一筆交易，賣出了公司股票的 9597 股。這些股票的平均價格為 11.98 美元，總交易額為 114972.06 美元。交易完成後，首席財務官在公司擁有 633680 股股票，價值 7591486.40 美元。該交易已在提交給證券交易委員會的文件中披露，可以通過此超鏈接訪問。此外，Zentalis Pharmaceuticals 的內部人員 Diana Hausman 於 5 月 9 日星期四出售了 3356 股公司股票。股票的平均價格為 12.62 美元，總價值為 42352.72 美元。交易完成後，該內部人員現在直接持有公司 373876 股股票，價值 4718315.12 美元。該交易已在提交給證券交易委員會的文件中披露，可在 SEC 網站上查看。此外，首席財務官 Cam Gallagher 於 5 月 31 日星期五進行了一筆交易，賣出了 9597 股公司股票。股票的平均價格為 11.98 美元，總價值為 114972.06 美元。交易完成後，首席財務官現在直接持有公司 633680 股股票，價值 7591486.40 美元。此次交易的披露信息可在此處找到。目前有 6.10% 的股票由公司內部人員持有。</p>
<h2>機構投資者對 Zentalis Pharmaceuticals 的看法</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了他們在該公司的持股。Quest Partners LLC 在第四季度購入了 Zentalis Pharmaceuticals 的新頭寸，價值約 38000 美元。Tower Research Capital LLC TRC 在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 252.3%，現在擁有 3615 股公司股票，價值 55000 美元，比上季度增加了 2589 股。Exchange Traded Concepts LLC 在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 34.0%，現在擁有 5989 股公司股票，價值 91000 美元，比上季度增加了 1519 股。中國通用資產管理有限公司在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 352.6%，現在擁有 8188 股公司股票，價值 124000 美元，比上季度增加了 6379 股。最後，OneAscent Financial Services LLC 在第四季度購入了 Zentalis Pharmaceuticals 的新頭寸，價值 156000 美元。</p>
<h2>關於 Zentalis Pharmaceuticals（獲取免費報告）</h2>
<p>Zentalis Pharmaceuticals, Inc.是一家臨牀階段生物製藥公司，專注於發現和開發用於治療各種癌症的小分子治療藥物。其產品候選包括 ZN-c3，一種 WEE1 抑制劑，用於治療晚期實體腫瘤和血液惡性腫瘤；目前正在進行 II 期臨牀試驗，作為子宮漿液性癌治療的單藥療法；在 Cyclin E1 驅動的高級別漿液性卵巢癌、輸卵管癌或原發性腹膜癌中進行 II 期臨牀試驗；與 PARPi 聯合用於鉑類耐藥性卵巢癌的 I/II 期臨牀試驗；與化療聯合用於鉑類耐藥性卵巢癌、腹膜或輸卵管癌的 Ib 期臨牀試驗；與化療聯合用於復發或難治性骨肉瘤的 I/II 期臨牀試驗；與 encorafenib 和 cetuximab 聯合用於突變轉移性結直腸癌的 I/II 期臨牀試驗；以及與化療聯合用於胰腺癌的 I/II 期臨牀試驗。</p>
<h2>更多閲讀</h2>
<ul>
<li>五隻我們比 Zentalis Pharmaceuticals 更喜歡的股票</li>
<li>投資高市盈率成長股</li>
<li>Signet Jewelers 股票在盈利下滑後有望反彈</li>
<li>逐步購買便宜股票的方法</li>
<li>Airship AI 獲得新合同：股價飆升 16%，還有更多</li>
<li>銀行股 - 最值得投資的銀行股</li>
<li>Restoration Hardware 股票：盈利下滑後是否值得購買？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA"/></p>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 拜登將推出 “FedNOW” [立即轉移您的資金]（來自 Priority Gold）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDQz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDQz"/></p>
<h2>現在是否值得投資$1,000 在 Zentalis Pharmaceuticals？</h2>
<p>在考慮投資 Zentalis Pharmaceuticals 之前，您需要聽到這個消息。</p>
<p>MarketBeat 跟蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單...而 Zentalis Pharmaceuticals 不在其中。</p>
<p>雖然 Zentalis Pharmaceuticals 目前在分析師中有 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ZNTL

<p>Zentalis Pharmaceuticals（納斯達克股票代碼：ZNTL）已經被瑞銀集團從 “買入” 評級下調為 “中性” 評級。該公司的價格目標也從 28.00 美元降低至 5.00 美元。其他分析師也發佈了下調評級並降低了該公司的價格目標。該股週四開盤價為 4.14 美元，市場普遍看法為 “持有”，共識價格目標為 11.33 美元。Zentalis Pharmaceuticals 報告了季度超出預期的盈利結果，但其股價一直在下跌</p>

<p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) was downgraded by investment analysts at UBS Group from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a research report issued on Thursday, Briefing.com reports. They presently have a $5.00 price objective on the stock, down from their previous price objective of $28.00. UBS Group's price target indicates a potential upside of 20.77% from the company's previous close.</p>
<div class="lb-trans"><p>根據 Briefing.com 的報道，投資分析師在週四發佈的研究報告中，將 Zentalis Pharmaceuticals（納斯達克股票代碼：ZNTL）的評級從 “買入” 調降至 “中性”。他們目前將該股票的目標價格定為 5.00 美元，低於之前的 28.00 美元。UBS 集團的目標價格表明，相較於公司之前的收盤價，有 20.77% 的潛在上漲空間。</p>
</div><p>Other equities analysts have also recently issued research reports about the company. Wells Fargo &amp; Company cut Zentalis Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and decreased their price objective for the company from $29.00 to $9.00 in a research note on Tuesday. Stifel Nicolaus lowered their price objective on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. Morgan Stanley reissued an &#34;equal weight&#34; rating and set a $8.00 target price (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday. HC Wainwright lowered their price target on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday. Finally, Wedbush cut shares of Zentalis Pharmaceuticals from a &#34;neutral&#34; rating to an &#34;underperform&#34; rating and cut their price objective for the stock from $15.00 to $4.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $11.33.</p>
<div class="lb-trans"><p>其他股票分析師最近也發佈了關於該公司的研究報告。富國銀行公司將 Zentalis Pharmaceuticals 的評級從 “超重” 調降至 “持平”，並將其目標價格從 29.00 美元降至 9.00 美元。Stifel Nicolaus 將 Zentalis Pharmaceuticals 的目標價格從 32.00 美元降至 10.00 美元，併為該公司設定了 “買入” 評級。摩根士丹利重新確認了 “持平” 評級，並將 Zentalis Pharmaceuticals 的目標股價設定為 8.00 美元（之前為 38.00 美元）。HC Wainwright 將 Zentalis Pharmaceuticals 的目標股價從 40.00 美元降至 20.00 美元，併為該公司設定了 “買入” 評級。最後，Wedbush 將 Zentalis Pharmaceuticals 的股票評級從 “中性” 調降至 “表現不佳”，並將其目標價格從 15.00 美元降至 4.00 美元。一位研究分析師給予該股票賣出評級，六位持有評級，三位給予買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，共識目標價格為 11.33 美元。</p>
</div><p><strong>Read Our Latest Analysis on ZNTL</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 ZNTL 的最新分析</strong></p>
</div><h2>Zentalis Pharmaceuticals Stock Down 50.7 %</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 股價下跌 50.7%</h2>
</div><p>Shares of Zentalis Pharmaceuticals stock opened at $4.14 on Thursday. The firm has a market cap of $294.06 million, a PE ratio of -1.24 and a beta of 1.83. Zentalis Pharmaceuticals has a 52 week low of $3.93 and a 52 week high of $30.53. The business's fifty day simple moving average is $11.53 and its 200-day simple moving average is $13.08.</p>
<div class="lb-trans"><p>週四，Zentalis Pharmaceuticals 股票開盤價為 4.14 美元。該公司市值為 2.9406 億美元，市盈率為-1.24，貝塔係數為 1.83。Zentalis Pharmaceuticals 的 52 周最低價為 3.93 美元，最高價為 30.53 美元。該公司的 50 天簡單移動平均線為 11.53 美元，200 天簡單移動平均線為 13.08 美元。</p>
</div><p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analyst estimates of $35.00 million. During the same quarter last year, the business posted ($1.07) EPS. As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals（納斯達克股票代碼：ZNTL）於 5 月 7 日星期二公佈了其季度收益結果。該公司季度每股盈利為 0.14 美元，高於預期的（0.77）美元。該季度公司營收為 4056 萬美元，超過分析師預期的 3500 萬美元。去年同期，該公司每股虧損為（1.07）美元。作為一組，股票分析師預計 Zentalis Pharmaceuticals 今年將每股虧損 2.72 美元。</p>
</div><h2>Insider Activity at Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 內部交易活動</h2>
</div><p>In related news, CFO Cam Gallagher sold 9,597 shares of the firm's stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the sale, the chief financial officer now owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of the firm's stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total value of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares of the company's stock, valued at $4,718,315.12. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Cam Gallagher sold 9,597 shares of the business's stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares in the company, valued at $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>據相關消息，首席財務官 Cam Gallagher 於 5 月 31 日星期五進行了一筆交易，賣出了公司股票的 9597 股。這些股票的平均價格為 11.98 美元，總交易額為 114972.06 美元。交易完成後，首席財務官在公司擁有 633680 股股票，價值 7591486.40 美元。該交易已在提交給證券交易委員會的文件中披露，可以通過此超鏈接訪問。此外，Zentalis Pharmaceuticals 的內部人員 Diana Hausman 於 5 月 9 日星期四出售了 3356 股公司股票。股票的平均價格為 12.62 美元，總價值為 42352.72 美元。交易完成後，該內部人員現在直接持有公司 373876 股股票，價值 4718315.12 美元。該交易已在提交給證券交易委員會的文件中披露，可在 SEC 網站上查看。此外，首席財務官 Cam Gallagher 於 5 月 31 日星期五進行了一筆交易，賣出了 9597 股公司股票。股票的平均價格為 11.98 美元，總價值為 114972.06 美元。交易完成後，首席財務官現在直接持有公司 633680 股股票，價值 7591486.40 美元。此次交易的披露信息可在此處找到。目前有 6.10% 的股票由公司內部人員持有。</p>
</div><h2>Institutional Investors Weigh In On Zentalis Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Zentalis Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at about $38,000. Tower Research Capital LLC TRC raised its position in shares of Zentalis Pharmaceuticals by 252.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company's stock valued at $55,000 after purchasing an additional 2,589 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Zentalis Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company's stock valued at $91,000 after buying an additional 1,519 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Zentalis Pharmaceuticals by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company's stock worth $124,000 after buying an additional 6,379 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $156,000.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了他們在該公司的持股。Quest Partners LLC 在第四季度購入了 Zentalis Pharmaceuticals 的新頭寸，價值約 38000 美元。Tower Research Capital LLC TRC 在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 252.3%，現在擁有 3615 股公司股票，價值 55000 美元，比上季度增加了 2589 股。Exchange Traded Concepts LLC 在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 34.0%，現在擁有 5989 股公司股票，價值 91000 美元，比上季度增加了 1519 股。中國通用資產管理有限公司在第四季度將其在 Zentalis Pharmaceuticals 的持股增加了 352.6%，現在擁有 8188 股公司股票，價值 124000 美元，比上季度增加了 6379 股。最後，OneAscent Financial Services LLC 在第四季度購入了 Zentalis Pharmaceuticals 的新頭寸，價值 156000 美元。</p>
</div><h2>About Zentalis Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Zentalis Pharmaceuticals（獲取免費報告）</h2>
</div><p>Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc.是一家臨牀階段生物製藥公司，專注於發現和開發用於治療各種癌症的小分子治療藥物。其產品候選包括 ZN-c3，一種 WEE1 抑制劑，用於治療晚期實體腫瘤和血液惡性腫瘤；目前正在進行 II 期臨牀試驗，作為子宮漿液性癌治療的單藥療法；在 Cyclin E1 驅動的高級別漿液性卵巢癌、輸卵管癌或原發性腹膜癌中進行 II 期臨牀試驗；與 PARPi 聯合用於鉑類耐藥性卵巢癌的 I/II 期臨牀試驗；與化療聯合用於鉑類耐藥性卵巢癌、腹膜或輸卵管癌的 Ib 期臨牀試驗；與化療聯合用於復發或難治性骨肉瘤的 I/II 期臨牀試驗；與 encorafenib 和 cetuximab 聯合用於突變轉移性結直腸癌的 I/II 期臨牀試驗；以及與化療聯合用於胰腺癌的 I/II 期臨牀試驗。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Zentalis Pharmaceuticals</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Signet Jewelers Stock Poised for Rebound After Earnings Drop</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>Airship AI Lands New Contract: Stock Soars 16% and More to Come</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Restoration Hardware Stock: Should You Buy After Earnings Drop?</li>
</ul>
<div class="lb-trans"><h2>更多閲讀</h2>
<ul>
<li>五隻我們比 Zentalis Pharmaceuticals 更喜歡的股票</li>
<li>投資高市盈率成長股</li>
<li>Signet Jewelers 股票在盈利下滑後有望反彈</li>
<li>逐步購買便宜股票的方法</li>
<li>Airship AI 獲得新合同：股價飆升 16%，還有更多</li>
<li>銀行股 - 最值得投資的銀行股</li>
<li>Restoration Hardware 股票：盈利下滑後是否值得購買？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ZNTL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold)(Ad)</p>
<div class="lb-trans"><p>→ 拜登將推出 “FedNOW” [立即轉移您的資金]（來自 Priority Gold）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDQz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8043&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Zentalis Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Zentalis Pharmaceuticals？</h2>
</div><p>Before you consider Zentalis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Zentalis Pharmaceuticals 之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單...而 Zentalis Pharmaceuticals 不在其中。</p>
</div><p>While Zentalis Pharmaceuticals currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Zentalis Pharmaceuticals 目前在分析師中有 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Zentalis Pharmaceuticals（納斯達克代碼：ZNTL）在瑞銀集團的評級被降為 “中性”